Licensing exercise based on SurgVision’s fluorescent marker, bevacizumab–IRDye 800CW

In watching the interview with SurgVision’s former CEO Ton van den Hoven, we learned that SurgVision entered into a licensing agreement with Roche to use Roche’s monoclonal antibody bevacizumab after being conjugated to the fluorescent dye IRDye 800CW by SurgVision.